A Aralex Aachen research explorer

Company ROR OpenAlex

Galapagos (Netherlands) Sign in to save

159 stored papers · Search its papers → · Its authors →

Papers 159

POS0660 CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS
2021 Annals of the Rheumatic Diseases article Medicine Rheumatoid Arthritis Research and Therapies Open access

2

citations
THU0204 A SUBGROUP ANALYSIS OF LOW DISEASE ACTIVITY AND REMISSION FROM PHASE 3 STUDY OF FILGOTINIB IN PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DMARDS
2020 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access

2

citations
OP0141 EFFECTS OF FILGOTINIB ON SPINAL LESIONS IN ANKYLOSING SPONDYLITIS: MAGNETIC RESONANCE IMAGING DATA FROM THE TORTUGA TRIAL
2021 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access

2

citations
OP25 Efficacy of filgotinib in patients with Ulcerative Colitis by line of therapy in the phase 2b/3 SELECTION trial
2021 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease

2

citations
P517 Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studies
2022 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease

2

citations
POS0235 INTEGRATED SAFETY ANALYSIS UPDATE FOR FILGOTINIB (FIL) IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS (RA) RECEIVING TREATMENT OVER A MEDIAN OF 2.2 YEARS (Y)
2022 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access

2

citations
POS0829 SAFETY AND EFFICACY OF FILGOTINIB: AN UPDATE FROM THE DARWIN 3 PHASE 2 LONG-TERM EXTENSION WITH A MAXIMUM OF 8.2 YEARS OF EXPOSURE
2023 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access

2

citations
High complete response rates, low dropout rate, and low-grade toxicities in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) receiving GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 DLBCL cohort
2025 Blood conference-abstract Medicine CAR-T cell therapy research

2

citations
Targeted exploration of an RNA sequencing dataset of preserved and lesioned oa cartilage-establishing a human oa disease model of chondrocyte hypertrophy
2021 Osteoarthritis and Cartilage article Medicine Osteoarthritis Treatment and Mechanisms Open access

1

citations
Combination Of Computational Methods With A Drug Repurposing Strategy Identifies A Compound Targeting Chondrocyte Hypertrophy
2023 Osteoarthritis and Cartilage article Medicine Osteoarthritis Treatment and Mechanisms Open access

1

citations
546. Transmission of Candida auris FKS1 Mutations in Orange County, CA
2026 Open Forum Infectious Diseases article Medicine Antifungal resistance and susceptibility Open access

1

citations
NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy
2026 Nature Communications article Medicine CAR-T cell therapy research Open access

1

citations
siRNA-based identification of IBD-related targets in human monocyte-derived dendritic cells
2021 Journal of Immunological Methods article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access

1

citations
POS0678 CLINICAL OUTCOMES OF METHOTREXATE (MTX)-NAIVE RHEUMATOID ARTHRITIS (RA) PATIENTS (pts) ON FILGOTINIB (FIL) LONG-TERM EXTENSION (LTE) TRIAL INITIALLY ON FIL OR MTX DURING THE PHASE 3 PARENT STUDY (PS)
2022 Annals of the Rheumatic Diseases article Medicine Rheumatoid Arthritis Research and Therapies Open access

1

citations
OP0224 FILGOTINIB TREATMENT LEADS TO RAPID AND SUSTAINED REDUCTIONS IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE PSORIATIC ARTHRITIS
2020 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access

1

citations
FRI0285 FILGOTINIB TREATMENT RESULTS IN REDUCTION OF BIOMARKERS ASSOCIATED WITH DISEASE IN PATIENTS WITH ANKYLOSING SPONDYLITIS
2020 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access

1

citations
POS1038 THE EFFECT OF FILGOTINIB ON ENTHESITIS: 100-WEEK DATA FROM AN OPEN-LABEL EXTENSION STUDY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
2021 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access

1

citations
POS1049 EFFECT OF FILGOTINIB ON PASDAS: DRIVERS OF LOW AND VERY LOW ACTIVITY UP TO WEEK 100
2021 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access

1

citations
P46 Efficacy and safety of long-term treatment with filgotinib for ulcerative colitis: data from SELECTIONLTE
2022 Poster presentations conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease

1

citations
P690 Prolonged benefit of filgotinib in patients with Ulcerative Colitis in SELECTION
2023 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access

1

citations

Most cited authors